Table 1 Main objectives of the 24 articles eligible for inclusion in this review

1

Dagli-Hernandez et al. [15]

To review clinical trials on pharmacogenomics of statins regarding the Brazilian population

2

Rosales et al. [21]

To evaluate the response to atorvastatin in Chilean hypercholesterolemic patients with PMs^a in ABCB1^b, CYP3A5^c, and CYP3A4^c genes

3

Shitara, Sugiyama. [24]

To review statins' PK^d and physicochemical issues and specific aspects such as PMs^a that could affect PK^d

4

Kivistö et al. [25]

To investigate whether CYP3A5^c expression results in poor response to statin therapy in Caucasians

5

Zubiaur et al. [26]

To evaluate the impact of SLCO1B1^e phenotype on atorvastatin exposure by conducting a candidate gene pharmacogenetic research

6

He et al. [27]

To assess the influence of CYP3A4*1G^c variant on atorvastatin PK^d in China's Han subjects with CAD^f

7

Park et al. [28]

To evaluate the contributions of CYP3A5^c and CYP3A4^c to atorvastatin metabolism

8

Maekawa et al. [29]

To assess, in vitro, the influence of CYP3A4*18^c and CYP3A4*16^c on the enzymatic function required for the metabolism of several drugs, including atorvastatin

9

Jani et al. [30]

To investigate CYP450^c genetic PMs^a among Gujarat subjects in India depending on atorvastatin as a probe

10

Poduri et al. [31]

To examine the influence of PMs^a of six specific genes on the therapeutic effect of statins in subjects suffering CAD^f

11

Gao et al. [32]

To investigate the influence of CYP3A4*1G^c PM^a on statins therapy

12

Peng et al. [33]

To illustrate the association between CYP450^c genetic PMs^a and response to atorvastatin in Chinese patients with ischemic stroke

13

Kajinami et al. [34]

To study the effect of three CYP3A4^c variant alleles on atorvastatin treatment

14

Willrich et al. [35] 

To summarize findings from previous studies on variations in responses to statins due to CYP3A^c PMs^a

15

Kadam et al. [36]

To screen LDL-C^g level after atorvastatin treatment in Indian carriers of genetic PMs^a in several enzymes involved in the pharmacodynamics and PK^d of statins

16

Klein et al. [37]

To examine the effect of genetic mutations on the phenotype of CYP3A4^c in human hepatocytes and participants using atorvastatin

17

Kolovou et al. [38]

To investigate the effect of CYP3A5*3^c PMs^a on the lipid profile after atorvastatin or simvastatin treatment

18

Willrich et al. [39]

To assess the impact of CYP3A5^c PMs^a on statins efficacy in 139 hypercholesterolemic Brazilians

19

Vrablik et al. [40]

To review literature about statin-induced myopathy

20

Becker et al. [41]

To investigate the influence of CYP3A4^c and ABCB1^b PMs^a on intolerance to atorvastatin or simvastatin treatment

21

Xia et al. [42]

To develop and validate a UHPLC-MS/MS^h approach for studying atorvastatin calcium PK^d in healthy carriers of certain genotypes

22

Liu et al. [43]

To explore the impact of microRNA on the inherited malfunctioning CYP3A4/5^c enzymes and atorvastatin metabolism

23

Wilke et al. [44]

To investigate the assumption that carriers of CYP3A5*3^c or CYP3A4*1B^c are at risk of myopathy due to atorvastatin

24

Benes et al. [45]

To review the risks for ADRsⁱ of commonly recommended statins